CLINUVEL PHARMACEUTICALS LIMITED (CUV)
Share Price Analysis and Chart
Enter the company code or Name for stock analysis:
CUV - CLINUVEL PHARMACEUTICALS LIMITED
FNArena Sector :
Pharmaceuticals & Biotech/Lifesciences
Year End: June
GICS Industry Group : Pharmaceuticals, Biotechnology & Life Sciences
Index: ASX200 | ASX300 | ALL-ORDS
FNArena Sector : Pharmaceuticals & Biotech/Lifesciences
Year End: June
Clinuvel is a biopharmaceutical company that develops and commercialises treatments for patients with genetic, metabolic and life threatening disorders. The company was founded and listed in 2001.
| LAST PRICE | CHANGE +/- | CHANGE % | VOLUME |
|---|---|---|---|
|
$15.42
25 May |
OPEN $16.21 |
HIGH $16.48 |
102,767 LOW $15.41 |
-0.860| OTHER COMPANIES IN THE SAME SECTOR | |||
| ACR . AHZ . CSL . IDT . IVX . MSB . MYX . RNO . OSL . TFC . TIS . KZA . AGH . FTT . PAR . ADO . PYC . RAC . RCE . ZNO . AVH . LGP . SPL . ARX . AFP . 1AD . TLX . PNV . MVP . BNO . NXS . GSS . EOF . NEU . PAL . PBP . BOT . IMU . MDC . IMM . PXS . HXL . MXC . OPT . ANP . | |||
FNARENA'S MARKET CONSENSUS FORECASTS
- No Record -
Last ex-div: 02/09 - ex-div 2.5c (franking 0%)
HISTORICAL DATA ARE ALL IN AUD
Copyright © 2022 FactSet UK Limited. All rights reserved
| Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| EPS Basic | xxx | xxx | xxx | xxx | xxx | 50.1 |
| DPS All | xxx | xxx | xxx | xxx | xxx | 2.5 |
| Sales/Revenue | xxx | xxx | xxx | xxx | xxx | 48.0 M |
| Book Value Per Share | xxx | xxx | xxx | xxx | xxx | 199.8 |
| Net Operating Cash Flow | xxx | xxx | xxx | xxx | xxx | 19.3 M |
| Net Profit Margin | xxx | xxx | xxx | xxx | xxx | 51.54 % |
EPS Basic
DPS All
Sales/Revenue
Book Value Per Share
Net Operating Cash Flow
Net Profit Margin
| Title | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 |
|---|---|---|---|---|---|---|
| Return on Capital Employed | xxx | xxx | xxx | xxx | xxx | 28.69 % |
| Return on Invested Capital | xxx | xxx | xxx | xxx | xxx | 28.33 % |
| Return on Assets | xxx | xxx | xxx | xxx | xxx | 26.01 % |
| Return on Equity | xxx | xxx | xxx | xxx | xxx | 28.69 % |
| Return on Total Capital | xxx | xxx | xxx | xxx | xxx | 30.50 % |
| Free Cash Flow ex dividends | xxx | xxx | xxx | xxx | xxx | 17.2 M |
Return on Capital Employed
Return on Invested Capital
Return on Assets
Return on Equity
Return on Total Capital
Free Cash Flow ex dividends
This is work in progress. Bear with us. It'll be amazing.
EXPERT VIEWS
Display All Commentary
Sentiment Indicator
No. Of Recommendations
CUV STOCK CHART
FNArena News on CUV
| 1 |
Australian Broker Call *Extra* Edition – May 09, 2022May 09 2022 - Daily Market Reports |
| 2 |
Rudi’s View: A Bear Market Anomaly That ConfusesMay 05 2022 - Rudi's View |
| 3 |
Australian Broker Call *Extra* Edition – Feb 24, 2022Feb 24 2022 - Daily Market Reports |
| 4 |
Australian Broker Call *Extra* Edition – Feb 10, 2022Feb 10 2022 - Daily Market Reports |
| 5 |
The Short Report – 03 Feb 2022Feb 03 2022 - Weekly Reports |
Latest Pharmaceuticals & Biotech/Lifesciences News
| 1 |
CSL: Buy Trigger AheadApr 26 2022 - Technicals |
| 2 |
Why CSL Fell Sharply YesterdayDec 17 2021 - Australia |
| 3 |
Beating The Biotech BluesSep 14 2021 - International |
| 4 |
Uncertainty Prevails For CSLAug 19 2021 - Australia |
| 5 |
Flying High – Medicinal Marijuana In AustraliaJul 26 2021 - Australia |
| 6 |
Wesfarmers On Drugs?Jul 13 2021 - Australia |
| 7 |
Is CSL’s Plasma Recovery Now Priced In?Jun 23 2021 - Australia |
| 8 |
CSL: Buy The DipJun 22 2021 - Technicals |
| 9 |
CSL To Retest Its High?May 25 2021 - Technicals |
| 10 |
Treasure Chest: CSL Plasma At Turning Point?May 05 2021 - Treasure Chest |